BridgeLine Translational Partners
Diligence-Grade Preclinical Strategy from Discovery Through IND
We build preclinical roadmaps with each study specified, designed for regulatory alignment, and packaged to answer every question investors and pharma partners will ask.
Complimentary. 30 minutes. No obligation.
What You Get
A Complete Preclinical Development Plan
Every study specified. Built for scrutiny from day one.
The Preclinical Roadmap is our signature engagement: a diligence-grade development plan covering your path from current data through IND-enabling. You walk away with a document you can put in front of your board, your investors, or a pharma partner the same week.
Unmet Need & Positioning
Where does your program fit? You get a defensible thesis covering target rationale, indication selection, competitive landscape, and differentiation.
Preclinical Roadmap
Your development plan, study by study: models, endpoints, success criteria, timelines, budgets, and CRO recommendations from current data through IND-enabling.
Path to Clinic
IND/CTA strategy, dose rationale, regulatory alignment, and nonclinical submission outline. The regulatory path that gets you to a filing-ready position.
Investor-Ready Deliverables
Risk registers, gap analysis, visual timelines, and executive summaries you can put in front of your board, investors, or a pharma partner the same week.
The Development Arc — Discovery to IND
Discovery
Target validation
Lead Selection
Candidate optimization
Efficacy & POC
Proof of concept studies
IND-Enabling
GLP tox & safety
IND / CTA
Regulatory filing
Discovery
Target validation
Lead Selection
Candidate optimization
Efficacy & POC
Proof of concept studies
IND-Enabling
GLP tox & safety
IND / CTA
Regulatory filing
What Your Deliverable Looks Like
Every study specified. Built for scrutiny from day one.
You walk away with a document you can put in front of your board, your investors, or a pharma partner the same week. Visual timelines, budget tables, risk assessments, and executive summaries, ready to use without a translation layer.
How It Works
Three steps from first conversation to investor-ready deliverables.
Strategy Call
Complimentary · 30 minutes
Walk us through your program and the decisions ahead. We assess fit and recommend the right starting point.
Strategy Diagnostic
1-2 weeks
Identifies your critical gaps, risks, and near-term priorities. You walk away knowing exactly which studies to run next and in what order.
Preclinical Roadmap
2-4 weeks · Signature engagement
Your complete development plan: study-level detail, unmet need analysis, regulatory path, and deliverables ready for the boardroom.
Who We Work With
Early-stage biotech companies building preclinical programs in gene therapy, RNA therapeutics, biologics, and related modalities.
Deep experience across leading modalities
Operator-to-Acquirer Lens
The plans we build answer the questions investors and pharma BD teams actually ask.
Experience spans Cephalon (now Teva), Sarepta Therapeutics, Spark Therapeutics (Roche), StrideBio, and the NIH. Designed and executed IND-enabling preclinical programs across gene therapy, RNA therapeutics, and biologics. Evaluated companies as acquisition/partnership targets and supported diligence on transactions valued up to $11B.
What Clients and Colleagues Say
From leaders at Parallel Bio, Lilly, Bound Therapeutics, and Sarepta Therapeutics.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Frequently Asked Questions
Common questions about BridgeLine and how we work.
Ready to Build a Plan That Holds Up?
Book a Strategy Call. Complimentary, 30 minutes, no obligation. We'll discuss your program and recommend the right starting point.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com